Opdivo/Yervoy combo beats chemo on PFS in lung cancer
Bristol-Myers Squibb has revealed that a combination of its immunotherapies Opdivo and Yervoy was superior to chemo alone in keeping disease progression at bay in patients with non-small cell lung cancer (NSCLC).
Read More
